HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Gene therapy represents ‘new paradigm’ for treatment of hematologic disorders
-
- The year of living dangerously Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- FDA approves digestive enzyme cartridge for enteral tube feeding
- FDA approves Keytruda for first-line treatment of metastatic melanoma
- FDA grants breakthrough therapy designation to BI 1482694 for NSCLC
- FDA grants Cellceutix rare pediatric disease designation for Kevetrin to treat retinoblastoma
- FDA grants orphan drug designation to GBT 440 for sickle cell disease
- FDA issues final guidance on blood donations from MSM
- FDA issues safety alert for antifungal medication dosages, approves label revisions
-
- Ablative therapies show promise for advanced pancreatic cancer
- ACS: Cancer death rate declines 23% from all-time high
- Cediranib plus chemotherapy effective for cervical cancer
- Swallowing disorders may warrant routine esophagoscopy examination in patients with HNSCC
- USPSTF breast cancer screening recommendations remain unchanged despite controversy
- AACR honors professor with breast cancer research lectureship
- Association of Pediatric Hematology/Oncology Nurses presents awards
- Cancer researcher to lead Einstein’s Belfer Institute
-
- Genomics expert joins Children’s Hospital of Philadelphia
- Society presents awards to MD Anderson professor
- University of Michigan Cancer Center names associate director
- Anastrozole, tamoxifen demonstrate similar efficacy, different safety profiles for DCIS
- Early PET scans guide de-escalation of therapy for advanced Hodgkin’s lymphoma
- Eltrombopag improves platelet counts, reduces fatigue for some patients with severe thrombocytopenia
- Hydroxyurea shows promise for stroke prevention in pediatric patients with sickle cell anemia
- Idelalisib combination reduces risk for progression, death in refractory CLL
-
- Interim PET scans predict relapse of non-bulky early-stage Hodgkin’s lymphoma
- Liquid biopsy could help guide prostate cancer treatment
- Midostaurin confers OS, EFS benefits in FLT3-mutated AML
- Recombinant Factor VIII products increase inhibitor development in severe hemophilia A
- Regular aspirin intake reduces risk for lethal prostate cancer
- Breast-conserving therapy extends OS in early-stage breast cancer
- Biosimilars may expand drug access, reduce costs, but still much to learn Jai N. Patel, PharmD, BCOP, CPP